We’re thrilled to share that we are taking a leading role in Milaboratories’ Series A funding round, joining forces with Ten13VC, Speedinvest, Acrobator Ventures and also alongside several angel investors from around the world. This marks an exciting chapter for the Milaboratories’ team and we couldn’t be more enthusiastic to support their work in genomic data analysis.
MiLaboratories specializes in cutting-edge software that unlocks genomic data to map immune responses. Their flagship product, MiXCR, harnesses the power of AI and cloud computing to process and decode complex genomic datasets. MiXCR has already earned widespread recognition from pharmaceutical companies and academic institutions for its critical role in accelerating drug discovery for COVID19 and other diagnostic breakthroughs.
Since 2009, MiLaboratories' leadership team—CTO Dmitriy Bolotin, CSO Dmitriy Chudakov, and CEO Stanislav Poslavsky—has been advancing the field of adaptive immunity through numerous academic publications and research with household names such as the FDI. Their deep commitment to research led them to develop their R&D algorithm that became the foundation for MiXCR.
They have then worked alongside household names in the biotech and pharmaceutical industry such as Modern and Bristol-Myers Squibb among many. Over time, that original idea has evolved into something even more powerful: Platforma.
The teams’ journey up until today is as much about their focus and speed of technological development to define a new category around programmable biology as it is about the strategic decisions made by leadership. They have found a new home in Bilbao, Spain as the base for their operations as the Basque city offers a unique blend of factors that align perfectly with what the company needs at this stage.
Bilbao, known for its innovation ecosystem, access to a rich talent pool and strong ties to both academia and industry, coupled with supportive government policies (and, of course, great gastronomy) provided the perfect backdrop for the MiLaboratories team to scale their research and business efforts.
Platforma is a cloud-based AI platform designed to process vast amounts of genomic data with incredible speed. Imagine processing being able to process an immense 1TB of genomic data on a standard MacBook Pro in just one hour, a task that previously took days. For our team at Leadwind, we get excited when we meet platforms that democratize access to advanced analytical tools. MiLaboratories’ Platforma empowers biologists with user-friendly tools, freeing bioinformaticians to focus on more complex tasks, thus improving efficiency across the board.
Beyond speed, Platforma also shines in its flexibility. With their newly-introduced Software Development Kit (SDK), researchers can now build custom analytical “blocks” tailored to their unique needs. This open and collaborative approach is designed to empower the scientific community, allowing them to contribute, customize, and collaborate through an open marketplace of ideas.
“We believe that opening our platform to the developer community will accelerate the adoption of modern computational tools, setting the next level of biomedical research,” said Stan Poslavsky, CEO of MiLaboratories. “Today, therapy development is driven by data, algorithms, and AI. Our mission is to make cutting-edge computational advances accessible to researchers as they work towards discovering new drugs.”
The MiLaboratories team is starting a new exciting chapter with the launch of Platforma. At Leadwind, we love partnering with contrarian founders who combine technical expertise with a bold vision. Stanislav and his team are committed to simplifying and accelerating DNA analysis and breaking down barriers in science.
Thanks to their software, scientists can now develop immune-based therapies, create diagnostic tools, and design personalized treatments more efficiently, accelerating progress in healthcare innovation.
The company will use this round of funding to continue to accelerate product development and build out its offering as the global leader in the Next-Generation Sequencing space by establishing its go-to-market team and expanding its offering for academia, developers and bioinformaticians all across.
We look forward to working together with our fellow investors and supporting the team as they continue to push and grow their vision! Vamos!
“Investing in platforms that bridge the gap between developers (in this case bioinformaticians) and business users (in this case biologists) is at the core of what we want to do in our fund. There is tremendous potential in democratizing access to complex data enabling the delivery of Immunological insights" - Miguel Arias, General Partner at Leadwind
We’re thrilled to share that we are taking a leading role in Milaboratories’ Series A funding round, joining forces with Ten13VC, Speedinvest, Acrobator Ventures and also alongside several angel investors from around the world. This marks an exciting chapter for the Milaboratories’ team and we couldn’t be more enthusiastic to support their work in genomic data analysis.
MiLaboratories specializes in cutting-edge software that unlocks genomic data to map immune responses. Their flagship product, MiXCR, harnesses the power of AI and cloud computing to process and decode complex genomic datasets. MiXCR has already earned widespread recognition from pharmaceutical companies and academic institutions for its critical role in accelerating drug discovery for COVID19 and other diagnostic breakthroughs.
Since 2009, MiLaboratories' leadership team—CTO Dmitriy Bolotin, CSO Dmitriy Chudakov, and CEO Stanislav Poslavsky—has been advancing the field of adaptive immunity through numerous academic publications and research with household names such as the FDI. Their deep commitment to research led them to develop their R&D algorithm that became the foundation for MiXCR.
They have then worked alongside household names in the biotech and pharmaceutical industry such as Modern and Bristol-Myers Squibb among many. Over time, that original idea has evolved into something even more powerful: Platforma.
The teams’ journey up until today is as much about their focus and speed of technological development to define a new category around programmable biology as it is about the strategic decisions made by leadership. They have found a new home in Bilbao, Spain as the base for their operations as the Basque city offers a unique blend of factors that align perfectly with what the company needs at this stage.
Bilbao, known for its innovation ecosystem, access to a rich talent pool and strong ties to both academia and industry, coupled with supportive government policies (and, of course, great gastronomy) provided the perfect backdrop for the MiLaboratories team to scale their research and business efforts.
Platforma is a cloud-based AI platform designed to process vast amounts of genomic data with incredible speed. Imagine processing being able to process an immense 1TB of genomic data on a standard MacBook Pro in just one hour, a task that previously took days. For our team at Leadwind, we get excited when we meet platforms that democratize access to advanced analytical tools. MiLaboratories’ Platforma empowers biologists with user-friendly tools, freeing bioinformaticians to focus on more complex tasks, thus improving efficiency across the board.
Beyond speed, Platforma also shines in its flexibility. With their newly-introduced Software Development Kit (SDK), researchers can now build custom analytical “blocks” tailored to their unique needs. This open and collaborative approach is designed to empower the scientific community, allowing them to contribute, customize, and collaborate through an open marketplace of ideas.
“We believe that opening our platform to the developer community will accelerate the adoption of modern computational tools, setting the next level of biomedical research,” said Stan Poslavsky, CEO of MiLaboratories. “Today, therapy development is driven by data, algorithms, and AI. Our mission is to make cutting-edge computational advances accessible to researchers as they work towards discovering new drugs.”
The MiLaboratories team is starting a new exciting chapter with the launch of Platforma. At Leadwind, we love partnering with contrarian founders who combine technical expertise with a bold vision. Stanislav and his team are committed to simplifying and accelerating DNA analysis and breaking down barriers in science.
Thanks to their software, scientists can now develop immune-based therapies, create diagnostic tools, and design personalized treatments more efficiently, accelerating progress in healthcare innovation.
The company will use this round of funding to continue to accelerate product development and build out its offering as the global leader in the Next-Generation Sequencing space by establishing its go-to-market team and expanding its offering for academia, developers and bioinformaticians all across.
We look forward to working together with our fellow investors and supporting the team as they continue to push and grow their vision! Vamos!
“Investing in platforms that bridge the gap between developers (in this case bioinformaticians) and business users (in this case biologists) is at the core of what we want to do in our fund. There is tremendous potential in democratizing access to complex data enabling the delivery of Immunological insights" - Miguel Arias, General Partner at Leadwind
